A night interrupted by heat is exhausting. When someone mentions a new non-hormonal tablet called Lynkuet, you might want to know two things before anything else: does it help, and could it be an option where you live? For women in India, those questions need separate answers.
Elinzanetant, sold as Lynkuet in markets where it is authorised, has evidence from randomised trials for reducing moderate-to-severe menopausal hot flashes. It also has precautions worth discussing before anyone considers taking it. Its overseas approval does not establish that it is approved or stocked in India. Here is what the evidence and current regulator information tell us, checked on 4 October 2026.
What elinzanetant does
Hot flashes are linked in part to changes in the brain’s temperature-control signalling when oestrogen falls. One of the messengers involved is neurokinin B. Elinzanetant blocks two receptors in this signalling network, NK1 and NK3. It is a neurokinin receptor antagonist, not an oestrogen tablet or an antidepressant. The European Medicines Agency’s Lynkuet overview describes its action and the symptoms it is authorised to treat in the EU.
You may already have heard of fezolinetant (Veozah). That medicine blocks NK3, while elinzanetant blocks NK1 and NK3. The extra receptor target is a pharmacological difference, not proof that one pill works better than the other for a particular woman. There is no direct comparative trial in the evidence cited here. Our separate fezolinetant guide covers that medicine in detail; this article focuses on elinzanetant.
These tablets target hot flashes and night sweats. If your main concern is vaginal dryness, bone health, or a changing menstrual cycle, ask your doctor about those symptoms separately. A tablet that helps with temperature symptoms does not automatically address every effect of menopause. Our overview of treatment choices shows where medicines and non-drug measures fit together.
How much relief did the OASIS trials find?
In two randomised, placebo-controlled studies, OASIS 1 and OASIS 2, participants kept daily records of moderate-to-severe hot flashes. At week 12, the treatment groups had about 3.2 fewer hot flashes per day than placebo in each trial, measured as the adjusted difference in change from baseline. Women in both the treatment and placebo groups improved; the figure is the additional average reduction associated with elinzanetant, not the total drop in the treated group. The difference was also present at week 4. The trials assessed severity, sleep disturbance and menopause-related quality of life as well (Pinkerton et al., JAMA, 2024, PMID 39172446).
It helps to interpret that average carefully. It does not promise that each woman will have precisely three fewer episodes. Baseline symptoms varied across participants, and the studies were conducted outside India. Most women in the pivotal studies were postmenopausal; someone still having irregular periods should not assume that results apply to her in the same way. If you are earlier in the transition, a clinician can first work out whether your symptoms are hot flashes and what else might be affecting your sleep.
OASIS 3 followed women for a longer period. At week 12, the adjusted between-group difference in daily moderate-to-severe hot flash frequency was 1.6 episodes, favouring elinzanetant. That trial enrolled a broader population without the minimum hot-flash frequency required in OASIS 1 and 2, so its different result should not be treated as a contradiction. Longer-term sleep and quality-of-life analyses were descriptive, not definitive proof of a particular sleep benefit (Panay et al., JAMA Internal Medicine, 2025, PMID 40920404).
There is also a distinct clinical situation: women receiving endocrine therapy for hormone-receptor-positive breast cancer or its prevention. OASIS 4 studied hot flashes in that population and found fewer daily episodes with elinzanetant than placebo at weeks 4 and 12 (Cardoso et al., New England Journal of Medicine, 2025, PMID 40454634). This is symptom evidence, not evidence that the tablet treats cancer or changes recurrence risk. The EMA’s current Lynkuet overview includes hot flashes caused by adjuvant endocrine therapy in its EU indication. If you are on tamoxifen or an aromatase inhibitor, make any medicine decision together with your oncology team; approval and prescribing details vary by country.
Dr. Suganya Venkat, an OB-GYN with over 15 years of experience, discusses hot-flash treatments in the context of your medical history during online consultations. If symptoms are disrupting your days or nights, message her on WhatsApp about your options rather than looking for an unverified imported tablet.
Side effects and checks to discuss first
Non-hormonal does not mean free of precautions. The current US Lynkuet prescribing information in the openFDA label record, reviewed 4 October 2026, lists headache, fatigue, dizziness and sleepiness among commonly reported adverse reactions. Sleepiness or dizziness may affect driving and other activities requiring alertness. Bedtime administration is part of the US-labelled regimen, but do not start, stop or adjust a prescription based on a blog post.
The FDA label calls for liver blood tests before treatment and a follow-up evaluation after starting. It also directs clinicians to consider symptoms that could signal liver injury. This is different from copying the monitoring schedule of fezolinetant: the medicines have their own labels. Tell your doctor about known liver disease and any medicines or supplements you take, so they can check interactions and whether this treatment is appropriate. In the US label, grapefruit and certain medicines affecting CYP3A4 require particular attention. Do not change an existing medicine on your own to make room for another.
The US label also warns about seizure risk, particularly relevant if you have a seizure history or other factors that lower the seizure threshold. Pregnancy is a contraindication under that label. Because some women with hot flashes are still able to conceive, your doctor needs to know whether pregnancy is possible before considering the medicine. These are screening conversations, not reasons to assume that something bad will happen to you. If you notice a worrying new symptom while taking any prescribed treatment, contact the prescriber promptly.
If you would rather start with measures that do not involve a new prescription, or you need an option that is available locally, our non-hormonal hot flash treatment guide discusses other approaches. They each have their own benefits and limitations; you do not have to rank them by how new they are.
Elinzanetant vs fezolinetant: what can you compare?
| Question | Elinzanetant (Lynkuet) | Fezolinetant (Veozah) |
|---|---|---|
| Brain signalling target | NK1 and NK3 receptors | NK3 receptor |
| Hormonal treatment? | No | No |
| Evidence discussed here | OASIS randomised trials, including a separate endocrine-therapy study | Different SKYLIGHT studies; see the linked guide |
| Liver-related precautions | Follow its own local prescribing information | Follow its own local prescribing information |
| Which is more effective? | A head-to-head answer is not established | A head-to-head answer is not established |
The FDA Lynkuet label and the FDA Veozah label describe different medicines and precautions. Their results should not be ranked by comparing percentages from separate studies: trial entry criteria, baseline symptom levels and measurement approaches differ. A clinician choosing between available treatments would also consider your other medicines, liver history, reproductive status and whether hot flashes are the main problem.
A medicine can be promising and still be unsuitable for someone with a particular medical history. If HRT is already working for you, a new non-hormonal option does not automatically mean you need to change it. If HRT is not appropriate or you would prefer to avoid it, there are established alternatives to discuss while you check local availability. For context on how long symptoms may last, see how long hot flashes last.
Is Lynkuet approved or sold in India? What does it cost?
The US FDA Drugs@FDA record records approval of Lynkuet in October 2025. The EMA Lynkuet medicine page says it received EU marketing authorisation in November 2025. These approvals apply to their respective jurisdictions. They do not, by themselves, permit a claim that a pharmacy in India can supply it.
For India, this article makes no claim about local approval, pharmacy availability or price. The overseas regulator pages above cannot answer those questions. Please do not treat an online listing, foreign price or currency conversion as an Indian retail price. Ask your prescribing doctor or a licensed Indian pharmacist to check current regulatory status and supply before making a plan. In the meantime, consider what relief you can access and supervise safely now.
If hot flashes are affecting work, sleep or everyday comfort, write down when they occur, what you have tried and which symptoms matter most to you. That short record will make a consultation more useful than trying to choose a brand name alone. You can also talk about HRT where appropriate, prescription non-hormonal options, and practical adjustments to sleep and room temperature. The best next step depends on your history, not on which medicine was most recently approved abroad.
Frequently asked questions
1. Is elinzanetant the same medicine as fezolinetant?
No. Both target neurokinin signalling without giving oestrogen, but elinzanetant blocks NK1 and NK3 receptors while fezolinetant blocks NK3. Their trial programmes and prescribing labels differ. A direct trial establishing which works better is not provided by the studies discussed here.
2. How soon did hot flashes improve in the trials?
The OASIS 1 and 2 trials found a difference from placebo by week 4, and assessed results again at week 12 (Pinkerton et al., JAMA, 2024, PMID 39172446). Individual response can vary. Your doctor can help decide when and how to assess whether a prescribed treatment is helping.
3. Does Lynkuet contain hormones?
No. Elinzanetant is a neurokinin receptor antagonist, not an oestrogen or progesterone product. Being non-hormonal does not remove the need to check other medicines, liver health and pregnancy possibility before treatment (see the US prescribing information).
4. What side effects should I ask about?
The US label lists headache, fatigue, dizziness and sleepiness among common adverse reactions. It also includes precautions concerning liver tests, daytime impairment, seizure risk and pregnancy. Ask your clinician to review your own medical history and the current label in your country before taking it.
5. Can someone on breast cancer endocrine therapy use it?
OASIS 4 found reduced hot flashes in women receiving endocrine therapy for hormone-receptor-positive breast cancer or its prevention (Cardoso et al., New England Journal of Medicine, 2025, PMID 40454634). The EMA lists this symptom indication in the EU. Eligibility elsewhere can differ; discuss treatment with the oncology team, including any other medicines you use.
6. Can I buy Lynkuet in India, and what is its price?
This article does not state that Lynkuet is approved or stocked in India, or give an Indian price as of 4 October 2026. Overseas approval and online advertisements are not proof of local supply. Ask a licensed Indian pharmacist or your doctor to check the status before considering it.
7. Do I need a new pill if my hot flashes are manageable?
Not necessarily. If symptoms are mild or your present plan helps, there is no reason to change treatment just because a new medicine exists. If sleep or daily life is being affected, review your symptoms and options with your doctor; treatment can be tailored to what you need.
If you would like to review your hot flashes, current medicines and available options without being pushed towards a particular pill, WhatsApp Dr. Suganya Venkat for an online consultation. Menolia consultations are online, so you can discuss this from anywhere in India.
